Your browser is no longer supported. Please, upgrade your browser.
BMY Bristol-Myers Squibb Company daily Stock Chart
Bristol-Myers Squibb Company
IndexS&P 500 P/E80.85 EPS (ttm)0.94 Insider Own0.10% Shs Outstand1.69B Perf Week-0.42%
Market Cap127.61B Forward P/E23.43 EPS next Y3.23 Insider Trans-20.86% Shs Float1.67B Perf Month5.22%
Income1.57B PEG3.46 EPS next Q0.66 Inst Own74.30% Short Float0.96% Perf Quarter7.64%
Sales16.91B P/S7.55 EPS this Y-22.30% Inst Trans-0.06% Short Ratio2.69 Perf Half Y18.84%
Book/sh8.62 P/B8.78 EPS next Y25.68% ROA4.90% Target Price76.48 Perf Year13.48%
Cash/sh2.55 P/C29.63 EPS next 5Y23.35% ROE10.70% 52W Range50.64 - 77.12 Perf YTD11.26%
Dividend1.52 P/FCF- EPS past 5Y-12.20% ROI4.60% 52W High-1.87% Beta0.50
Dividend %2.01% Quick Ratio1.30 Sales past 5Y-3.20% Gross Margin76.00% 52W Low49.44% ATR1.11
Employees25000 Current Ratio1.50 Sales Q/Q8.70% Oper. Margin11.60% RSI (14)62.49 Volatility1.04% 1.37%
OptionableYes Debt/Eq0.47 EPS Q/Q0.50% Profit Margin9.30% Rel Volume0.89 Prev Close75.50
ShortableYes LT Debt/Eq0.46 EarningsJul 28 BMO Payout159.00% Avg Volume5.95M Price75.68
Recom2.30 SMA201.93% SMA504.28% SMA20013.49% Volume5,271,429 Change0.24%
May-23-16Initiated Hilliard Lyons Neutral
Apr-29-16Reiterated UBS Buy $73 → $80
Apr-29-16Reiterated Barclays Equal Weight $70 → $75
Apr-06-16Initiated Societe Generale Sell $48
Jan-22-16Upgrade Berenberg Hold → Buy
Dec-02-15Upgrade Guggenheim Neutral → Buy
Dec-01-15Reiterated Barclays Equal Weight $55 → $70
Aug-24-15Upgrade Piper Jaffray Underweight → Neutral
Jun-17-15Initiated Piper Jaffray Underweight $60
May-14-15Initiated Berenberg Hold $70
Apr-21-15Upgrade Morgan Stanley Equal-Weight → Overweight $60 → $80
Feb-27-15Reiterated Argus Buy $70 → $78
Jan-12-15Reiterated Argus Buy $62 → $70
Oct-27-14Reiterated MKM Partners Sell $34 → $36
Jul-25-14Reiterated MKM Partners Sell $29 → $34
Jan-15-14Reiterated Argus Buy $58 → $62
Jan-10-14Upgrade Barclays Equal Weight → Overweight $52 → $65
Dec-20-13Reiterated UBS Neutral $48 → $54
Jul-29-13Reiterated Argus Buy $54
Jul-17-13Reiterated Barclays Equal Weight $42 → $45
Jul-24-16 07:59AM  The Economy, Interest Rates, Earnings and the Markets
Jul-22-16 06:04PM  Pharma Industry Outlook: Fundamentals Remain Strong
04:44PM  5 Big Drugmakers Reporting Earnings Next Week
01:15PM  What Role Did Innovative Medicines Play in Novartiss 2Q16 Earnings?
01:14PM  How Did Johnson & Johnsons Segments Perform in 2Q16?
11:19AM  Will Q2 Earnings Hold a Surprise for Nielsen (NLSN) Stock?
Jul-21-16 07:48AM  13 Companies to Watch From MIT's Smart 50 List, Including 4 Buys
Jul-20-16 03:28PM  ResMed (RMD) Q4 Earnings: Disappointment in the Cards?
11:39AM  Bristol-Myers Squibb Announces Availability of FDA-Approved ORENCIA┬« (abatacept) ClickJect, a Self-Administered Subcutaneous Autoinjector, for Adults with Moderate to Severe Rheumatoid Arthritis Business Wire
08:14AM  Bristol-Myers Squibb Says FDA-Approved ORENCIA Is Available For Adults With Moderate To Severe Rheumatoid Arthritis
06:00AM  'Mad Money' Lightning Round: Take Bristol-Myers Over Juno
Jul-19-16 06:56PM  Bristol-Myers' Opdivo Label Expansion Under U.S., EU Review
08:22AM  5 Big Pharma Stocks Struggling to Raise Their Dividends at Motley Fool
07:20AM  Cambridges Jounce announces hefty $2.5B deal with Celgene for cancer drugs at
Jul-18-16 06:49PM  Valeant's (VRX) Brodalumab BLA Up for Review in the U.S.
04:56PM  Edwards Lifesciences (EW) Q2 Earnings: Will It Be a Miss?
07:58AM  Bristol-Myers Squibb Reveals Regulatory Approvals For Opdivo Marketing Application
06:59AM  Bristol-Myers Squibb Announces Regulatory Updates for Opdivo (nivolumab) in Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Business Wire
05:53AM  Herd Mentality
Jul-17-16 06:03AM  Herd Mentality
Jul-14-16 01:30PM  All-time high playbook
Jul-13-16 05:03PM  5 Things Celldex Therapeutics, Inc. Wants You to Know at Motley Fool
04:06PM  Bayer Expands Drug Discovery Collaboration with X-Chem
02:51PM  10 NYSE Stocks Hitting 52-Week Highs Tuesday at Insider Monkey
01:00PM  Top 7 Research Reports for July 13, 2016
Jul-12-16 10:07AM  Rova-T and Immuno-Oncology Therapies May Be Complementary
06:25AM  [$$] 5 Big Growth Stocks That Don't Get Enough Respect at
Jul-11-16 04:45PM  All is OK with the world, and that's fine for now
03:13PM  Why AbbVies Rova-T May Have More Growth Potential than Predicted
11:07AM  U.S. Companies On Hiring Sprees Across The Country
Jul-10-16 04:07PM  Sentiment Turns On A Dime
07:21AM  Here's How Pfizer's Protecting Its Kidney Cancer Drug From New Competitors at Motley Fool
Jul-08-16 09:00PM  Everything's Fine and Dandy; Jobs Are in the Rearview Mirror: Jim Cramer's Best Blogs
01:16PM  Top 7 Research Reports for July 8, 2016
11:34AM  Alnylam (ALNY) Begins Phase I/II Study on Chronic HBV Drug
09:41AM  The Reason Why Exelixis Skyrocketed 20.5% in June at Motley Fool
Jul-07-16 12:02PM  The Big Reason Behind Celgene Corporation's 13% Year-to-Date Tumble at Motley Fool
10:02AM  Bristol-Myers Buys Cormorant, Focus on Immuno-Oncology
07:06AM  Whats Really Driving Horizons Valuation?
Jul-06-16 12:07PM  Analyst Estimates for Pfizer: Why Should We Take Notice?
11:35AM  [$$] Top U.S. Pharma Themes for the Second Half at
10:37AM  Amgen's Kyprolis Gains Approval in EU for Label Expansion
09:05AM  Why AbbVie Continues to Explore Imbruvica for Diffuse Large B-Cell Lymphoma
07:30AM  [$$] Success of Pharma Immunotherapies Sparks Race Among Biotech Startups at The Wall Street Journal
01:04AM  [$$] Business Watch at The Wall Street Journal
Jul-05-16 04:27PM  How Gilead's New Hepatitis C Virus Combination Stacks Up to the Competition at Motley Fool
02:56PM  Bristol-Myers Brings Back One That Got Away at Bloomberg
09:51AM  UK cost agency rejects Bristol's Opdivo for kidney cancer Reuters
09:30AM featured highlights: Fresh Del Monte Produce, Post Holdings, Bristol-Myers Squibb, Southern National Bancorp of Virginia and Apple Hospitality REIT
09:30AM  Bristol-Myers Squibb, Deutsche Bank, Alphabet, Blucora and Internap highlighted as Zacks Bull and Bear of the Day
09:22AM  Bristol-Myers (BMY) Stock Slides on Swedish Acquisition
08:51AM  Bristol-Myers buys Swedish company with immunotherapy treatment at MarketWatch
08:42AM  [$$] Bristol-Myers Buys Swedish Firm With Immunotherapy Treatment at The Wall Street Journal
07:34AM  Bristol-Myers Squibb Buys Privately Held Cormorant Pharmaceuticals
06:59AM  Bristol-Myers Squibb Acquires Cormorant Pharmaceuticals Business Wire
Jul-04-16 11:06AM  Insights into Pfizers Profitability and Financial Guidance
09:06AM  XBiotech Xilonix Positive in Phase III Colorectal Cancer Study
07:08AM  Major Change Afoot
Jul-03-16 06:40AM  The Big Loser After Gilead's Latest Approval May Not Be Who You Think (Hint: It's not AbbVie, Inc.) at Motley Fool
Jul-01-16 04:30PM  Shire Stock Up Despite Mixed Data on Pipeline Candidate
12:30PM  Hunting for value
09:46AM  5 Low Beta Stocks to Withstand Market Volatility
08:28AM  Bristol-Myers, PsiOxus Strike Immuno-Oncology Collaboration
Jun-30-16 06:31PM  Tesaro Stock Up on Successful Phase III Ovarian Cancer Trial
06:28PM  McKesson Raises View Due to Accounting Changes, Stock Up
06:59AM  Bristol-Myers Squibb and PsiOxus Therapeutics Announce Immuno-Oncology Clinical Collaboration to Evaluate the Combination of Opdivo and Enadenotucirev Business Wire
Jun-29-16 06:33PM  These Large Pharmaceutical Stocks Should be on your Radar
01:10PM  How Pfizer, Merck May Feel Long-Term Pinch From Brexit
10:23AM  Bristol-Myers Trades Ex-Dividend Wednesday (BMY) at Investopedia
Jun-28-16 06:00PM  Life or Death: Why Chinese Patients Mix Drug Cocktails at Home at Bloomberg
04:19PM  FDA approves first pill to treat all forms of hepatitis C
11:50AM  Gilead HCV Pill Approved For Broad Usage, Priced Below Sovaldi
10:03AM  5 Medical Stocks to Buy with Great Dividend Yields
09:07AM  Mylans Profits: Can You Expect Changes?
09:00AM  Puma (PBYI) Submits Neratinib Marketing Application in EU
08:15AM  New Strong Buy Stocks for June 28th
Jun-27-16 08:17PM  Jim Cramer's 'Mad Money' Recap: 'Brexit' Is the Dumbest Financial Mistake Ever
05:31PM  Mylan Launches Generic Version of Glaxo's Avodart in U.S.
07:07AM  Bristol-Myers Squibb's bladder cancer treatment granted breakthrough therapy designation at MarketWatch
06:59AM  Bristol-Myers Squibbs Opdivo (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Advanced Form of Bladder Cancer Business Wire
Jun-26-16 11:17AM  The Sky Is Not Falling
Jun-24-16 06:07PM  Incyte Gains on Jakafi's Breakthrough Status for Acute GVHD
04:39PM  Brexit may make health care stocks a good defensive play at MarketWatch
04:10PM  Sickle Cell Partnership Creates Demonstration Project to Treat Children in Angola Business Wire
09:42AM  Why Investors Are Paying a Premium for These 3 Drugmakers at Motley Fool
Jun-22-16 07:01PM  Cramer: Let's Put Brexit in Its Historic Context
04:55PM  SolarCity and Bristol-Myers climb, Adobe and HP stumble
02:05PM  Whats so groundbreaking about Curis new cancer drug that just began human trials? at
10:53AM  GW Pharma (GWPH) to Develop Epidiolex for Infantile Spasms
08:36AM  Immuno-Oncology: The Strategic Supernova In Cancer Today at Forbes
Jun-21-16 04:21PM  3 Ways This $30 Billion Market Is Bristol's for the Taking at Motley Fool
11:22AM  Bristol-Myers Squibb Co. Value Analysis (NYSE:BMY) : June 21, 2016
Jun-20-16 04:20PM  BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhib
04:15PM  Murdo Gordon Appointed Executive Vice President and Chief Commercial Officer Business Wire
03:05PM  Epizyme Offers Early Data on Non-Hodgkin Lymphoma Drug
08:19AM  Bristol-Myers Squibb Co. breached its 50 day moving average in a Bearish Manner : BMY-US : June 20, 2016
08:00AM  Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan
04:46AM  Calls For Actions Grow Louder
Jun-17-16 09:45AM  Will Merck Keytruda Surpass Bristol-Myers Opdivo In Immunotherapies Race?
09:09AM  Cheniere Energy Inc. (LNG) and Vince Holding Corp (VNCE) See Their CEOs Buy Shares; Three Other Companies Register Insider Selling at Insider Monkey
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that targets and blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung cancer, renal cell cancer, and melanoma; Sprycel, a multi-targeted tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with metastatic melanoma; Abilify, an antipsychotic agent for adult patients with schizophrenia, bipolar mania disorder, and major depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor that is in regulatory review for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. The company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ANDREOTTI LAMBERTODirectorJul 08Sale75.0411,600870,461368,499Jul 11 05:12 PM
ANDREOTTI LAMBERTODirectorJul 07Sale73.8611,600856,776380,099Jul 11 05:12 PM
Blin EmmanuelSVP, Chief Strategy OfficerJul 02Option Exercise0.00951012,516Jul 06 05:58 PM
Cuss Francis MEVP & CSOJul 01Option Exercise0.003,6550291,628Jul 06 05:58 PM
Gordon MurdoEVP, Chief Commercial OfficerJul 01Option Exercise0.002,335014,950Jul 06 05:58 PM
ANDREOTTI LAMBERTODirectorJun 29Sale72.799,800713,342392,194Jun 30 05:42 PM
ANDREOTTI LAMBERTODirectorJun 28Sale71.6713,400960,396390,394Jun 30 05:42 PM
Elicker John ESVP, Public Affairs & IRJun 14Sale72.6911,820859,21955,011Jun 16 04:31 PM
Bancroft Charles AEVP & Chief Financial OfficerMay 20Sale70.7930,2012,137,838184,694May 24 05:04 PM
Caldarella Joseph CSVP & ControllerMay 16Sale72.473,519255,00455,238May 17 04:46 PM
Caforio GiovanniChief Executive OfficerMay 05Option Exercise0.008,0400134,549May 09 04:42 PM
Caforio GiovanniChief Executive OfficerMay 03Option Exercise24.7950,4551,250,602145,958May 05 04:31 PM
Caforio GiovanniChief Executive OfficerMay 03Sale71.3134,5942,466,885117,118May 05 04:31 PM
ANDREOTTI LAMBERTODirectorMay 02Option Exercise26.04234,7206,112,787671,514May 04 05:28 PM
Schmukler Louis SPres., Global Mfg. & SupplyMay 02Sale71.9522,2181,598,65221,971May 04 05:28 PM
ANDREOTTI LAMBERTODirectorMay 02Sale71.88234,72016,870,792436,794May 04 05:28 PM
ANDREOTTI LAMBERTODirectorApr 05Sale66.0011,600765,626436,794Apr 06 04:18 PM
ANDREOTTI LAMBERTODirectorApr 04Sale65.7911,600763,216448,394Apr 06 04:18 PM
JUDGE ANN POWELLSVP, Global Human ResourcesApr 01Option Exercise0.001,554025,260Apr 05 04:59 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.0031,624055,059Mar 14 09:44 PM
Cuss Francis MEVP & CSOMar 10Option Exercise0.0037,1430300,492Mar 14 09:43 PM
ANDREOTTI LAMBERTODirectorMar 10Option Exercise0.00204,4470574,101Mar 14 09:43 PM
Elicker John ESVP, Public Affairs & IRMar 10Option Exercise0.0020,860074,177Mar 14 09:43 PM
Caldarella Joseph CSVP & ControllerMar 10Option Exercise0.0020,460067,864Mar 14 09:44 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.0031,406089,478Mar 14 09:42 PM
Caforio GiovanniChief Executive OfficerMar 10Option Exercise0.0060,6230132,906Mar 14 09:42 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0057,4840366,730Mar 14 09:42 PM
JUDGE ANN POWELLSVP, Global Human ResourcesMar 10Option Exercise0.0025,435032,069Mar 14 09:43 PM
Nielsen AnneChief Compliance & Ethics OffMar 10Option Exercise0.008,806059,091Mar 14 09:41 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0075,6180247,158Mar 14 09:41 PM
Blin EmmanuelSVP, Head of CommercializationMar 10Option Exercise0.0011,707013,498Mar 14 09:42 PM
Gordon MurdoSVP, Head of Worldwide MarketsMar 10Option Exercise0.0019,309019,608Mar 14 09:41 PM
CAMPBELL LEWIS BDirectorMar 08Option Exercise24.962,50062,4002,500Mar 10 04:36 PM
CAMPBELL LEWIS BDirectorMar 08Sale66.002,500165,0000Mar 10 04:36 PM
Caforio GiovanniChief Executive OfficerMar 06Option Exercise0.002,889079,627Mar 08 04:42 PM
Gordon MurdoSVP, Head of Worldwide MarketsMar 06Option Exercise0.001,28202,611Mar 08 04:43 PM
Nielsen AnneChief Compliance & Ethics OffMar 06Option Exercise0.00724050,821Mar 08 04:43 PM
Caldarella Joseph CSVP & ControllerMar 06Option Exercise0.001,931048,253Mar 08 04:43 PM
LEUNG SANDRAEVP, General CounselMar 06Option Exercise0.005,5740315,121Mar 08 04:41 PM
Elicker John ESVP, Public Affairs & IRMar 06Option Exercise0.001,043053,715Mar 08 04:41 PM
Cuss Francis MEVP & CSOMar 06Option Exercise0.003,0100269,043Mar 08 04:42 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 06Option Exercise0.002,391060,032Mar 08 04:40 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 06Option Exercise0.007,3240169,885Mar 08 04:40 PM
Blin EmmanuelSVP, Head of CommercializationMar 06Option Exercise0.0081901,553Mar 08 04:41 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 06Option Exercise0.002,528024,746Mar 08 04:40 PM
Caldarella Joseph CSVP & ControllerMar 04Sale64.6412,962837,91646,322Mar 07 05:41 PM
Caforio GiovanniChief Executive OfficerFeb 17Option Exercise22.8920,125460,66188,778Feb 19 04:32 PM
LEUNG SANDRAEVP, General CounselFeb 17Option Exercise22.7314,560330,949319,699Feb 19 04:32 PM
LEUNG SANDRAEVP, General CounselFeb 17Sale63.5710,152645,342309,547Feb 19 04:32 PM
Caforio GiovanniChief Executive OfficerFeb 17Sale63.5812,040765,52776,738Feb 19 04:32 PM
ANDREOTTI LAMBERTODirectorFeb 04Option Exercise0.00148,1800445,820Feb 08 04:31 PM
Paliwal Dinesh CDirectorFeb 01Option Exercise0.003,25703,257Feb 03 06:28 PM
ANDREOTTI LAMBERTODirectorJan 05Sale68.1911,600791,028310,424Jan 06 04:40 PM
ANDREOTTI LAMBERTODirectorJan 04Sale66.9311,600776,332322,024Jan 06 04:40 PM
Elicker John ESVP Pub Affairs & Inv RelationJan 03Option Exercise0.00950053,012Jan 05 06:21 PM
ANDREOTTI LAMBERTODirectorDec 15Sale70.0511,600812,580332,852Dec 16 04:39 PM
ANDREOTTI LAMBERTODirectorDec 14Sale68.0011,600788,843344,452Dec 16 04:39 PM
ANDREOTTI LAMBERTODirectorNov 20Sale67.7611,600786,016501,052Nov 23 04:41 PM
ANDREOTTI LAMBERTODirectorNov 19Sale67.0211,600777,470512,652Nov 23 04:41 PM
Bancroft Charles AEVP & Chief Financial OfficerNov 01Option Exercise0.003,1000163,957Nov 03 03:45 PM
Elicker John ESVP Pub Affairs & Inv RelationNov 01Option Exercise0.00496052,286Nov 03 03:45 PM
ANDREOTTI LAMBERTODirectorOct 06Sale59.7311,600692,904524,252Oct 08 04:08 PM
ANDREOTTI LAMBERTODirectorOct 05Sale61.9911,600719,027535,852Oct 08 04:08 PM
ANDREOTTI LAMBERTODirectorSep 03Sale59.5711,600691,032546,874Sep 03 06:34 PM
ANDREOTTI LAMBERTODirectorSep 02Sale59.2211,600687,005558,474Sep 03 06:34 PM